Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $7.8200 (-6.68%) ($7.7200 - $8.2500) on Thu. Sep. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.98% (three month average) | RSI | 51 | Latest Price | $7.8200(-6.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.7% a day on average for past five trading days. | Weekly Trend | ADAP declines -2.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XLRE(26%) DRIV(23%) IWC(23%) XBI(23%) IWM(22%) | Factors Impacting ADAP price | ADAP will decline at least -1.99% in a week (0% probabilities). BNDX(-15%) TLT(-12%) VXX(-9%) TIP(-9%) BND(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.99% (StdDev 3.98%) | Hourly BBV | 0 () | Intraday Trend | -5.2% | | | |
|
1 - 5 Day Possible Target | $-0.06(-100.77%) | Resistance Level | $8.34 | 5 Day Moving Average | $8.27(-5.44%) | 10 Day Moving Average | $8.32(-6.01%) | 20 Day Moving Average | $8.34(-6.24%) | To recent high | -34.2% | To recent low | 0% | Market Cap | $1.209b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |